SD 1 formsdmay282021.htm SD Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts001-1404104-2882273
(State or other jurisdiction
of incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
125 Summer Street, Boston, MA02110
(Address of principal executive offices)(Zip Code)
William P. Burke
Executive Vice President, Chief Financial Officer
(781) 848-7100
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2020.



SECTION 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, Haemonetics Corporation (the “Company”) has filed this Form SD for the reporting period from January 1, 2020 to December 31, 2020.

A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available at http://www.haemonetics.com/about-us/corporate-responsibility/our-products/conflict-minerals-statement.

Item 1.02 Exhibit
Item 2.01 of this Form SD is incorporated by reference into this Item 1.02.

SECTION 2 - Exhibits
Item 2.01 Exhibits
(a) Exhibits
Exhibit NumberDescription
Conflict Minerals Report of Haemonetics Corporation




SIGNATURES
    
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
Date: May 28, 2021By:/s/ William P. Burke
Name:William P. Burke
Title:Executive Vice President, Chief Financial Officer